Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment
Discover the latest drugs and treatment options in the Hepatitis D Pipeline. Dive into DelveInsight's comprehensive report today! @ Hepatitis D Pipeline Outlook
Key Takeaways from the Hepatitis D Pipeline Report
In June 2025, Ribocure Pharmaceuticals AB announced clinical trial is to learn if drug RBD1016 works to treat chronic hepatitis D virus infection in adults. It will also learn about the safety of drug RBD1016. There will be 2 treatment groups - an active group (n=10) and a deferred active group (n=5), with participants allocated randomly. In the active group, participants will receive RBD1016. In the deferred active group, participants will receive 4 doses of placebo followed by deferred treatment with doses of RBD1016.
In June 2025, Vir Biotechnology Inc. conducted Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
DelveInsight's Hepatitis D Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Hepatitis D treatment.
The leading Hepatitis D Companies such as Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
Promising Hepatitis D Pipeline Therapies such as Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others.
Stay ahead with the most recent pipeline outlook for Hepatitis D. Get insights into clinical trials, emerging therapies, and leading companies with Hepatitis D @ Hepatitis D Treatment Drugs
Hepatitis D Emerging Drugs Profile
Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals
Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor's Xtend™ and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first asset in Vir Biotechnology's collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies. Currently, this combination drug product is in Phase III stage of its development for the treatment of Hepatitis D.
Brelovitug: Bluejay Therapeutics
Brelovitug is an investigational, highly potent, pan-genotypic, fully human IgG1 mAb that targets the anti-HBsAg on both the HDV and the HBV. Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for CHD, a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in CHB patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. Currently, the drug is in the Phase II/III stage of its development for the treatment of Hepatitis D.
RBD1016: Ribocure Pharmaceuticals AB
RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Currently, the drug is in Phase II stage of its development for the treatment of Hepatitis D.
The Hepatitis D Pipeline Report Provides Insights into-
The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment.
Hepatitis D Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market
Explore groundbreaking therapies and clinical trials in the Hepatitis D Pipeline. Access DelveInsight's detailed report now! @ New Hepatitis D Drugs
Hepatitis D Companies
Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Hepatitis D Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Unveil the future of Hepatitis D Treatment. Learn about new drugs, Hepatitis D Pipeline developments, and key companies with DelveInsight's expert analysis @ Hepatitis D Market Drivers and Barriers
Scope of the Hepatitis D Pipeline Report
Coverage- Global
Hepatitis D Companies- Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
Hepatitis D Pipeline Therapies- Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others.
Hepatitis D Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatitis D Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hepatitis D Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hepatitis D Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Hepatitis D: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hepatitis D– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Brelovitug: Bluejay Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug Name: Company Name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Hepatitis D Key Companies
Hepatitis D Key Products
Hepatitis D- Unmet Needs
Hepatitis D- Market Drivers and Barriers
Hepatitis D- Future Perspectives and Conclusion
Hepatitis D Analyst Views
Hepatitis D Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
36 minutes ago
- Globe and Mail
Prologis Stock Rises 10.3% in Three Months: Will the Trend Last?
Prologis Inc. PLD shares have gained 10.3% in the past three months, outperforming the industry 's growth of 6.3%. This industrial real estate investment trust (REIT) is well-poised to benefit from its portfolio of strategically located industrial real estate in some of the world's busiest distribution markets. Strategic buyouts and development activities appear promising. Its scale drives efficiency, and balance sheet strength aids its growth endeavors. Moreover, the company is also converting some of its warehouses into data centers to capitalize on the growing opportunity in this asset category. Analysts seem optimistic about this Zacks Rank #3 (Hold) company. The Zacks Consensus Estimate for its 2025 FFO per share has moved marginally northward over the past month to $5.70. Factors Behind PLD Stock Price Rise: Will This Trend Continue? Prologis provides industrial distribution warehouse space in some of the busiest distribution markets across the globe. The properties of the company are typically located in large, supply-constrained infill markets in close proximity to airports, seaports and ground transportation facilities, which facilitates rapid distribution of customers' products. The solid demand for Prologis' strategically located facilities is driving healthy operating performance over the past several quarters. Prologis continues to bolster its presence in high-barrier, high-growth markets through strategic acquisitions and development activities. In the first quarter of 2025, the company's share of acquisitions amounted to $811 million. Prologis has a high number of build-to-suit development projects. In the first quarter of 2025, development stabilization aggregated $925 million, with 64.5% being built to suit, while development starts totaled $646 million, with 78.0% being built to suit. The sites are positioned near large population centers, suited for serving as the last-mile warehouse before goods are delivered to consumers. Moreover, the data center industry is currently experiencing significant growth, driven by the demands of the evolving needs of today's digital economy, cloud and AI applications. To capitalize on this growing opportunity, Prologis is focusing on both warehouse conversions and ground-up developments. Prologis maintains a healthy balance sheet position with ample flexibility, which poises it well to capitalize on long-term growth opportunities. As of March 31, 2025, this industrial REIT had a total available liquidity of $6.52 billion. As of the same date, the company's weighted average interest rate on its share of the total debt was 3.2%, with a weighted average term of 8.7 years. Its credit ratings as of March 31, 2025 were A2 (Outlook Positive) from Moody's and A (Outlook Stable) from Standard & Poor's, enabling the company to borrow at an advantageous rate. Solid dividend payouts are arguably the biggest enticements for REIT shareholders, and Prologis remains committed to that. In the last five years, Prologis has increased its dividend five times, and its five-year annualized dividend growth rate is 13.71%. Given the company's solid operating platform, opportunities for growth and decent financial position compared with the industry, this dividend rate is expected to be sustainable in the near term. Key Risks for Prologis The choppiness in the industrial real estate market, with subdued demand, remains a concern for Prologis. Moreover, high borrowing expenses amid still elevated interest rates add to the company's woes. Stocks to Consider Some better-ranked stocks from the broader REIT sector are VICI Properties VICI and W.P. Carey WPC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for VICI Properties' 2025 FFO per share is pegged at $2.35, up 4% year over year. The Zacks Consensus Estimate for W.P. Carey's 2025 FFO per share stands at $4.88, up 3.8% year over year. Note: Anything related to earnings presented in this write-up represents FFO, a widely used metric to gauge the performance of REITs. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Prologis, Inc. (PLD): Free Stock Analysis Report W.P. Carey Inc. (WPC): Free Stock Analysis Report VICI Properties Inc. (VICI): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Globe and Mail
an hour ago
- Globe and Mail
Zacks Industry Outlook Highlights Mondelez International, Sysco, McCormick and Celsius
For Immediate Release Chicago, IL – July 3, 2025 – Today, Zacks Equity Research discusses Mondelez International, Inc. MDLZ, Sysco Corp. SYY, McCormick & Co. MKC and Celsius Holdings, Inc. CELH. Industry: Food - Miscellaneous The Zacks Food-Miscellaneous industry continues to face a tough macroeconomic backdrop, with persistent inflation weighing on consumer spending and accelerating the shift toward private-label alternatives. At the same time, rising input costs and increased operational expenses are squeezing profit margins across the sector. To navigate these pressures, food companies are embracing strategic initiatives centered on cost efficiency, product innovation and portfolio diversification. Industry leaders such as Mondelez International, Inc., Sysco Corp., McCormick & Co. and Celsius Holdings, Inc. are leveraging these efforts to drive growth in an evolving marketplace. About the Industry The Zacks Food-Miscellaneous industry consists of companies that manufacture and sell a wide range of food and packaged food items, such as cereals, flour, sauces, bakery items, spices and condiments, natural and organic food items and frozen products. Some companies also provide comfort food items, such as chocolates and ready-to-serve meals, soups and snacks. A few players are engaged in providing pet food products and supplements. Several food companies also offer organic and natural products. Companies operating in this space sell their products mainly through wholesalers, distributors, large retail organizations, grocery chains, mass merchandisers, drug stores and e-commerce service providers. Some also cater to foodservice channels, including restaurants, cafes and hotels. Others offer services to schools, hospitals and industry caterers. Major Trends Shaping the Future of the Food Industry Challenging Market Landscape: The food industry is facing a tough macroeconomic landscape, with persistent inflation and shrinking consumer spending power reshaping buying habits. Shoppers are increasingly opting for lower-cost alternatives, with private-label products gaining ground over traditional national brands. At the same time, reduced foot traffic in quick-service restaurants is contributing to weaker foodservice performance, putting pressure on sales in key markets. As a result, many leading food brands are reporting softer sales volumes. To combat these challenges, food companies are shifting strategies — emphasizing value-focused marketing, launching targeted promotional campaigns and expanding their portfolios with affordable, budget-friendly product lines to better meet evolving consumer demand. Cost Pressure: Food companies are under growing pressure as rising costs weigh heavily on margins. Elevated key input prices — such as raw ingredients, labor, packaging and transportation — are tightening profitability. On top of that, businesses are absorbing additional operational expenses tied to essential long-term investments in efficiency, performance upgrades, and capacity expansion. While necessary for future growth, these initiatives are creating short-term financial strain. Compounding the issue, global trade tensions and tariffs have further escalated input costs, especially for imported materials. In response, companies across the food sector are aggressively pursuing cost-control strategies — streamlining supply chains, optimizing sourcing, and implementing operational efficiencies — to protect margins and navigate this inflationary environment. Strengthening Brands and Revamping Portfolio: Established brands continue to provide a competitive edge, fueling strong customer loyalty and supporting business growth. This advantage, combined with a commitment to innovation, has helped companies maintain their market position. As demand for healthier and more nutritious products rises, companies are introducing innovative organic options and expanding their wellness-focused offerings. Beyond product development, efforts to modernize production capabilities and diversify product portfolios have delivered meaningful results. These initiatives have reinforced market positioning while paving the way for future expansion by ensuring adaptability to shifting consumer preferences and industry trends. The ability to stay aligned with evolving customer demands has become a crucial driver of success. Zacks Industry Rank Indicates Dull Prospects The Zacks Food-Miscellaneous industry is housed within the broader Zacks Consumer Staples sector. The industry currently carries a Zacks Industry Rank #187, which places it in the bottom 24% of more than 250 Zacks industries. The group's Zacks Industry Rank, which is the average of the Zacks Rank of all the member stocks, indicates dull near-term prospects. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Looking at the aggregate earnings estimate revisions, it appears that analysts are gradually losing confidence about this group's earnings growth potential. Since the beginning of April 2025, the industry's consensus earnings estimate for the current financial year has declined 3.1%. Let's take a look at the industry's performance and current valuation. Industry vs. Broader Market The Zacks Food-Miscellaneous industry has underperformed the S&P 500 and the broader Zacks Consumer Staples sector over the past year. The industry has declined 6.9% over this period against the S&P 500's growth of 12.5%. Meanwhile, the broader sector has gained 3.9% in the said time frame. Industry's Current Valuation On the basis of forward 12-month price-to-earnings (P/E), which is commonly used for valuing consumer staples stocks, the industry is currently trading at 15.85X compared with the S&P 500's 22.43X and the sector's 17.39X. Over the past five years, the industry has traded as high as 20.75X and as low as 14.47X, with the median being at 17.53X. 4 Food Stocks to Keep a Close Eye On Mondelez: This Zacks Rank #3 (Hold) company is a global powerhouse in the confectionery, food, beverage, and snack food industry. With a strong portfolio of iconic brands such as Oreo, Ritz, LU, Clif Bar, and Tate's Bake Shop — as well as premium chocolates like Cadbury Dairy Milk, Milka, and Toblerone — Mondelez continues to shape the future of snacking. The company is delivering consistent growth by focusing on its core categories, including chocolate, biscuits, and baked snacks. Strategic portfolio reshaping, ongoing investment in product innovation, and impactful brand activations are key drivers of Mondelez's long-term success. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. By enhancing brand relevance, optimizing operational efficiency, and maintaining disciplined cost management, Mondelez is well-positioned to sustain financial performance. Additionally, the company is investing in healthier snacking options to meet rising consumer demand for well-being and active lifestyle choices. The Zacks Consensus Estimate for Mondelez's current financial-year earnings per share (EPS) has remained unchanged at $3.02 in the last 30 days. Shares of MDLZ have gained 2.2% in the past year. Sysco: This Zacks Rank #3 company continues to capitalize on growth opportunities within the expanding food-away-from-home market, supported by its diversified operations and strategic initiatives. The company's "Recipe for Growth" framework is central to its long-term success, enhancing capabilities across sales, supply chain, and customer engagement. Sysco's five strategic pillars include elevating the customer experience through advanced digital tools, optimizing supply chain operations for greater efficiency and consistency, and delivering customer-focused merchandising and marketing solutions to drive sales. In addition, the company is strengthening its performance through team-based selling strategies and expanding into new channels, segments, and capabilities. Cost-efficiency remains a key focus, with Sysco making targeted investments backed by savings initiatives. The Zacks Consensus Estimate for SYY's current fiscal-year EPS has remained unchanged at $4.38 in the past 30 days. Shares of Sysco have gained 7.3% in a year. McCormick: This Zacks Rank #3 company is a global leader in flavor, known for manufacturing, marketing, and distributing herbs, spices, seasonings, condiments, and flavor solutions. The company's continued focus on innovation and expansion of its distribution footprint has reinforced its leadership across core product categories and key global markets. McCormick is leveraging several growth drivers — including robust brand marketing, cutting-edge product and packaging innovation, effective category management, and proprietary technology. The company's ability to drive revenues through increased volume, rather than relying solely on pricing strategies, underscores the strength and broad consumer appeal of its diverse brand portfolio. McCormick's Comprehensive Continuous Improvement (CCI) program plays a vital role in fueling strategic investments and enhancing operating margins. The Zacks Consensus Estimate for MKC's current financial-year EPS has moved down by a couple of cents to $3.02 in the past 30 days. Shares of McCormick have gained 8% in the past year. Celsius Holdings: This Zacks Rank #3 company has rapidly become one of the fastest-growing names in the beverage industry by positioning itself as a clean, health-conscious alternative to traditional energy drinks. Celsius Holdings' zero-sugar, clean-label offerings have gained strong traction among Gen Z and millennial consumers who value wellness, performance, and transparency. Product innovation continues to be a core growth engine for Celsius Holdings, enabling the brand to stay ahead of evolving consumer preferences. The company further strengthened its market position with the strategic acquisition of Alani Nu, completed on April 1, 2025. CELH has also made significant strides in expanding its retail distribution footprint, securing increased shelf space across major national and regional retailers. The Zacks Consensus Estimate for Celsius Holdings' current financial-year EPS has moved down by almost 9% to 81 cents in the last 30 days. Shares of CELH have declined 18.9% in the past year. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Sysco Corporation (SYY): Free Stock Analysis Report Mondelez International, Inc. (MDLZ): Free Stock Analysis Report Celsius Holdings Inc. (CELH): Free Stock Analysis Report
Globe and Mail
an hour ago
- Globe and Mail
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention ('CDC') adopted new recommendations for the use of RSV vaccines in the upcoming respiratory virus season. The revised recommendations lower the recommended age for RSV vaccination. Now, adults aged 50-59 who are at higher risk of severe illness from the disease are advised to receive a single dose of the vaccine. The previous CDC guidance recommended RSV vaccines for people aged 75 and older, as well as those aged between 60-74 who were at high risk of the disease. Per the CDC's website, this recommendation was officially adopted last week by the current HHS secretary, Robert F. Kennedy, Jr. Although the CDC director typically accepts or rejects such recommendations, the position is currently vacant, so Kennedy fulfilled that role. President Trump has backed Susan Monarez as his nominee for the post, but her appointment is still pending confirmation by the U.S. Senate. The broader recommendations come as a surprise because the members of the CDC's advisory committee — who initially made the recommendation earlier this year — were all removed by RFK Jr. last month. MRNA Stock Price Performance Year to date, the stock has lost 27% compared with the industry 's 2% decline. How Does the Revised CDC Guidance Benefit Moderna? The expanded CDC recommendations widen Moderna's addressable market for its RSV vaccine, mResvia. By lowering the recommended age group, the guidance opens up a new segment of eligible patients who were previously excluded. Moderna is one of a handful of companies marketing an RSV vaccine. Though mResvia was initially approved last year for use in people aged 60 and older, the FDA expanded its label last month to include high-risk individuals aged between 18-59. Despite commercially launching the vaccine last year, mResvia sales were modest as it was approved and recommended later in the contracting season. By that point, many people had already completed their vaccinations with either GSK 's GSK Arexvy or Pfizer 's PFE Abrysvo. RSV vaccines gained traction in 2023 with the initial approvals of Arexvy and Abrysvo — the first FDA-approved RSV vaccines. At the time, the CDC issued blanket approvals for use among individuals aged 60 and older. However, the CDC later narrowed that guidance, which trimmed the target market last year. That, combined with the earlier availability of GSK and Pfizer's offerings, gave both companies a dominant position over Moderna. Both GSK and Pfizer vaccines are already approved for use in individuals aged 60 and older. While GSK's Arexvy is approved for use in high-risk individuals aged 50-59, PFE's Abrysvo is approved for use in high-risk people aged 18-59. The Pfizer vaccine is also approved for use in infants through maternal immunization. MRNA's Zacks Rank Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report This article originally published on Zacks Investment Research (
